CML Publications from Africa

• The prognostic significance of TET2 single nucleotide polymorphism in Egyptian chronic myeloid leukemia
  Hamed NA et al. Mediterr J Hematol Infect Dis, January 2020 – open access publication
• Pre-therapeutic and evolutive characteristics of patients suffering from chronic myeloid leukemia in Abidjan, Ivory Coast
  Silué DA et al. Bull Cancer, June 2019 (in French)
• Acute ischemic intestinal necrosis as a rare side effect of nilotinib
  Li L et al. Niger J Clin Pract, January 2019
• Detection of BCR-ABL1 fusion gene transcripts in the saliva of Nigerian patients with chronic myeloid leukemia
  Uzoma IC et al. Niger J Clin Pract, January 2019

• Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?
  Adehin A et al. Leuk Lymphoma, May 2018
  (epub ahead of print)
• Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience)
  Ben Lakhal R et al. Ann Hematol, January 2018
  (epub ahead of print)
• Population pharmacokinetics of imatinib in Nigerians with chronic myeloid leukemia: Clinical implications for dosing and resistance
  Adeagbo BA et al. J Clin Pharmacol, December 2017
• Preliminary data on mircoRNA profiles in a group of South African patients diagnosed with chronic myeloid leukemia
  Prinsloo A et al. Mol Clin Oncol, September 2017 
• Downregulation of miR-451 in Tunesian chronic myeloid leukemia patients: potential implications in imatinib resistance
  Soltani I et al. Hematology, May 2018 
• hOCT1 gene expression predict for optimal response to imatinib in Tunisian patients with chronic myeloid leukemia
  Ben Hassine I et al. Cancer Chemother Pharmacol, April 2017 
• Epidemiological approach of chronic myeloid leukemia: Algerian-Tunesian Study
  Djouadi K et al. Blood, December 2016 
• Evaluation of the imatinib treatment of patients followed up for chronic myelogenous leukemia in Algeria
  Djouadi K et al. Blood, December 2016 
• Influence of CYP3A*3 and ABCB1 C3435T on clinical outcomes and through plasma concentrations of imatinib in Nigerians with chronic myeloid leukemia
  Adeagbo BA et al. J Clin Pharm Ther, October 2016
• Simple HPLC-UV method for pharmacokinetic studies of imatinib in the presence of common antimalarial agents
  Adeagbo BA et al. Journal of Liquid Chromatography & Related Technologies 2015, 38:1194-1198